Physician profile
Jessilin M Quint
NPI 1841603867
$366,492.10
in general payments reported to CMS, 2019-2025
22 companies · $143K in 2025
The $143K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,390 · 2020: $4,224 · 2021: $5,427 · 2022: $66K · 2023: $45K · 2024: $97K · 2025: $143K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $160K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $54K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Travel and Lodging: $20K · Food and Beverage: $9,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $160,131.25 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $54,137.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,390.00 |
| Travel and Lodging | $20,007.23 |
| Food and Beverage | $9,597.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $153,235.77 | 2019-2025 | Total30, Precision7, Dailies Total1 |
| Bausch & Lomb Americas INC. | $82,438.78 | 2023-2025 | Miebo, Xiidra, Infuse |
| Abbvie INC. | $64,441.28 | 2022-2025 | |
| Allergan, INC. | $34,991.29 | 2019-2022 | |
| Alcon Research LLC | $16,710.00 | 2024-2025 | |
| Dompe US, INC. | $6,804.46 | 2022-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $3,411.97 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $1,452.14 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $1,445.93 | 2019-2025 | |
| Carl Zeiss Meditec USA, INC. | $291.05 | 2022-2025 | Cirrus Hd-Oct |
| Johnson & Johnson Vision Care, INC. | $234.76 | 2019-2023 | Acuvue |
| Sight Sciences, INC. | $215.00 | 2019-2024 | Tearcare System |
| Biotissue Holdings INC. | $208.57 | 2023-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $174.94 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $93.92 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $93.75 | 2023-2024 | Misight Contact Lens |
| Astellas Pharma Global Development | $93.59 | 2024 | Izervay |
| Harrow Eye, LLC | $69.33 | 2025 | Vevye |
| Shire North American Group INC | $32.41 | 2019 | |
| Lkc Technologies, INC. | $19.79 | 2025 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Amgen INC. | $13.97 | 2025 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessilin Quint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.